Natural anti-HCV agents

Drugs of the Future

Volumn 34, Issue 3, 2009, Pages 223-236

  Fan, Hui ^a   Starks, Courtney M ^b   Hughey, Heidi ^b   Eldridge, Gary R ^b   Hu, Jin Feng ^a,b  

^a B326 Science Building   (China)

^b Sequoia Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,6 PENTA O GALLOYL BETA DEXTRO GLUCOSE; 1,2,3,6 TETRA O GALLOYL BETA DEXTRO GLUCOSE; 1,2,6 TRI O GALLOYL BETA DEXTRO GLUCOSE; 11 O (4 O METHYLGALLOYL)BERGENIN; 3,3' DIGALLOYLPROCYANIDIN B2; 3,3' DIGALLOYLPROPRODELPHINIDIN B2; ANTIVIRUS AGENT; BREVIFOLIN; BREVIFOLIN CARBOXYLIC ACID; CORILAGIN; CYANIDAN 3 OL; ELLAGIC ACID; EMBELIN; GLYCYRRHIZIC ACID; GOMISIN A; HEPATITIS C VACCINE; HUMULON; HYPERICIN; ISO ALPHA ACID; MELLEIN; NATURAL PRODUCT; NEOMINOPHAGEN C; OXYMATRINE; PARTHENOLIDE; PHYLLANTHUSIIN U; PLANT EXTRACT; SILYBUM MARIANUM EXTRACT; TELLIMAGRANDIN I; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHOHUMOL;

ALLERGY; ANTIVIRAL ACTIVITY; CHRONIC LIVER DISEASE; COST OF ILLNESS; DIARRHEA; GENOTYPE; HEPATITIS; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HEPATOBILIARY DISEASE; HUMAN; NONHUMAN; REVIEW;

EID: 76349088725     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.03.1344809     Document Type: Review

References (161)

1. Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244(4902): 359-62.
2. Kuo, G., Choo, Q.L., Alter, H.J. et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989, 244(4902): 362-4.
3. Alter, M.J., Hadler, S.C., Judson, F.N. et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. J Am Med Assoc (JAMA) 1990, 264(17): 2231-5.
4. Hoofnagle, J.H. Hepatitis C: The clinical spectrum of disease. Hepatology 1997, 26(3, Suppl. 1): 15S-20S.
5. Reding, M. Recent developments in hepatitis C antiviral research 1999-2000. Expert Opin Ther Pat 2000, 10: 1201-20.
6. Edlin, B.R., Carden, M.R. Injection drug users: The overlooked core of the hepatitis C epidemic. Clin Infect Dis 2006, 42(5): 673-6.
7. Armstrong, G.L., Wasley, A., Simard, E.P, McQuillan, G.M., Kuhnert, W.L., Alter, M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144(10): 705-14.
8. Centers for Disease Control and Prevention (CDC). Viral hepatitis C fact sheet, March 6, 2008: 1-2. Available at: www.cdc.gov/hepatitis. Accessed May 27, 2008.
9. Sherman, K. Antiviral drugs advisory committee volumes I, II, and summary minutes, Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Thursday, October 19-20, 2006. http://www.fda.gov/ohrms/dockets/ ac/cder06.html#AntiviralDrugs
10. Hagan, H., Snyder, N., Hough, E., Yu, T.J., McKeirnan, S., Boase, J., Duchin, J. Case-reporting of acute hepatitis B and C among injection drug users. J Urban Health 2002, 79(4): 579-85.
11. Guadagnino, V., Stroffolini, T., Rapicetta, M. et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy. Hepatology 1997, 26(4): 1006-11.
12. World Health Organization (WHO). The Hepatitis C Virus, 2002: 1-69. Available at http://www.who.int/csr/disease/hepatitis/Hepc.pdf. Accessed May 27, 2008.
13. Kamal, S.M., Fouly, A.E., Kamel, R.R. et al. Peginterferon alfa-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response. Gastroenterology 2006, 130(3): 632-8.
14. Di Bisceglie, A.M. Natural history of hepatitis C: Its impact on clinical management. Hepatology 2000, 31(4): 1014-8.
15. Goodman, Z.D., Ishak, K.G. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995, 15(1): 70-81.
16. Cohen, J. The scientific challenge of hepatitis C. Science 1999, 285(5424): 26-30.
17. Lohmann, V., Körner, F., Koch, J.-O., Herian, U., Theilmann, L., Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285(5424): 110-3.
18. Lauer, G.M., Walker, B.D. Hepatitis C virus infection. N Engl J Med 2001, 345(1): 41-52.
19. Vrolijk, J.M., Kaul, A., Hansen, B.E., Lohmann, V., Haagmans, B.L., Schalm, S.W., Bartenschlager, R. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J Virol Methods 2003, 110(2): 201-9.
20. Fanning, L.J. Anti-viral therapies for hepatitis C virus infection: Current options and evolving candidate drugs. Lett Drug Des Discov 2005, 2: 150-61.
21. Saravanan, S., Velu, V., Kumarasamy, N. et al. Coinfection of hepatitis B and hepatitis C virus in HIV-infected patients in south India. World J Gastroenterol 2007, 13(37): 5015-20.
22. . Bräu, N., Bini, E.J., Shahidi, A. et al. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol 2002, 97(8): 2071-8.
23. Wong, J.B., McQuillan, G.M., McHutchison, J.G., Poynard, T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000, 90(10): 1562-9.
24. Damen, M., Bresters, D. Hepatitis C treatment. In: Hepatitis C Virus. Current Studies in Hematology and Blood Transfusion. H.W. Reesink (Ed.). Karger: Basel, 1998, 181-207.
25. Kwong, A.D. Hepatitis C virus NS3/4A protease. Curr Opin Infect Dis 1997, 10: 485-90.
26. Manns, M.P., McHutchison, J.G., Gordon, S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001, 358(9286): 958-65.
27. Fried, M.W., Shiftman, M.L., Reddy, K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13): 975-82.
28. Huang, Z.H., Murray, M.G., Secrist, J.A. III. Recent development of therapeutics for chronic HCV infection. Antivir Res 2006, 71(2-3): 351-62.
29. Stauber, R.E., Stadlbauer, V. Novel approaches for therapy of chronic hepatitis C. J Clin Virol 2006, 36(2): 87-94.
30. Azzam, H.S., Goertz, C., Fritts, M., Jonas, W.B. Natural products and chronic hepatitis C virus. Liver Int 2007, 27(1): 17-25.
31. Stribling, R., Sussman, N., Vierling, J.M. Treatment of hepatitis C infection. Gastroenterol Clin North Am 2006, 35(2): 463-86.
32. Gish, R. Future therapies for hepatitis C. Medical writers' circle. (www.hcvadvocate.org. p.1-5. Feb 2006).
33. Dymock, B.W. Emerging therapies for hepatitis C virus infection. Expert Opin Emerg Drugs 2001, 6(1): 13-42.
34. Gordon, C.P., Keller, P.A. Control of hepatitis C: A medicinal chemistry perspective. J Med Chem 2005, 48(1): 1-20.
35. De Francesco, M.R.G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005, 436(7053): 953-60.
36. Chen, S.-H.,Tan, S.-L. Discovery of small-molecule inhibitors of HCV NS3- 4A protease as potential therapeutic agents against HCV infection. Curr Med Chem 2005, 12: 2317-42.
37. Boguszewska-Chachulska, A.M., Krawczyk, M., Najda, A., Kopanska, K., Stankiewicz-Drogon, A., Zagorski-Ostoja, W., Bretner, M. Searching for a new anti-HCV therapy: Synthesis and properties of tropolone derivatives. Biochem Biophys Res Commun 2006, 341(2): 641-7.
38. Llinàs-Brunet, M., Bailey, M., Fazal, G. et al. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett 1998, 8(13): 1713-8.
39. Ingallinella, P., Altamura, S., Bianchi, E. et al. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry 1998, 37(25): 8906-14.
40. Llinàs-Brunet, M., Bailey, M., Fazal, G. et al. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: Towards smaller inhibitors. Bioorg Med Chem Lett 2000, 10(20): 2267-70.
41. 1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 2002, 12(4): 701-4.
42. Colarusso, S., Gerlach, B., Koch, U. et al. Evolution, synthesis and SAR of tripeptide α-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease. Bioorg Med Chem Lett 2002, 12(4): 705-8.
43. Fischmann, T.O., Weber, P.C. Peptidic inhibitors of the hepatitis C virus serine protease within non-structural protein 3. Curr Pharm Des 2002, 8(28): 2533-40.
44. Colarusso, S., Koch, U., Gerlach, B. et al. Phenethyl amides as novel non-covalent inhibitors of hepatitis C virus NS3/4A protease: Discovery, initial SAR, and molecular modeling. J Med Chem 2003, 46(3): 345-8.
45. Yeh, C.-T., Hwang, D.-R., Lai, H.-Y., Hsu, J.T.A. Inhibition of authentic hepatitis C virus replication by sodium stibogluconate. Biochem Biophys Res Commun 2003, 310(2): 537-41.
46. Tsantrizos, Y.S., Bolger, G., Bonneau, P. et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew Chem Int Ed Engl 2003, 42(12): 1356-60.
47. Carroll, S.S., Tomassini, J.E., Bosserman, M. et al. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J Biol Chem 2003, 278(14): 11979-84.
48. Gopalsamy, A., Lim, K., Ciszewski, G. et al. Discovery of pyrano [3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors. J Med Chem 2004, 47(26): 6603-8.
49. Bailey, M.D., Halmos, T., Goudreau, N., Lescop, E., Llinàs-Brunet, M. Novel azapeptide inhibitors of hepatitis C virus serine protease. J Med Chem 2004, 47(15): 3788-99.
50. Rönn, R., Sandström, A. New developments in the discovery of agents to treat hepatitis C. Curr Top Med Chem 2008, 8(7): 533-62.
51. Fogden, E., Neuberger, J. Alternative medicines and the liver. Liver Int 2003, 23(4): 213-20.
52. Zou, J., Chen, H. S. Review on recent advances of anti-HCV drugs. Chin Pharm J 2004, 39: 403-8.
53. Coon, J.T., Ernst, E. Complementary and alternative therapies in the treatment of chronic hepatitis C: A systematic review. J Hepatol 2004, 40(3): 491-500.
54. Newman D.J., Cragg, G.M. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007, 70(3): 461-77.
55. Luper, S. A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev 1998, 3: 410-21.
56. Luper, S. A review of plants used in the treatment of liver disease: Part two. Altern Med Rev 1999, 4(3): 178-88.
57. Van Rossum, T.G.J., Vulto, A.G., De Man, R.A., Brouwer, J.T., Schalm, S.W. Review article: Glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 1998, 12(3): 199-205.
58. Liu, J.P., Manheimer, E., Tsutani, K., Gluud, C. Medicinal herbs for hepatitis C virus infection. Cochrane Database Syst Rev 2001, (4): CD003183.
59. Liu, J.P., Manheimer, E., Tsutani, K., Gluud, C. Medicinal herbs for hepatit is C virus infection: A Cochrane hepatobiliary systematic review of randomized trials. Am J Gastroenterol 2003, 98(3): 538-44.
60. Dhiman, R.K., Chawla, Y. K. Herbal medicines for liver diseases. Digest Dis Sci 2005, 50(10): 1807-12.
61. Patrick, L. Hepatitis C: Epidemiology and review of complementary/alternative medicine treatments. Altern Med Rev 1999, 4(4): 220-38.
62. Seeff, L.B., Lindsay, K.L., Bacon, B.R., Kresina, T.F., Hoofnagle, J.H. Complementary and alternative medicine in chronic liver disease. Hepatology 2001, 34(3): 595-603.
63. Levy, C., Seeff, L.D., Lindor, K.D. Use of herbal supplements for chronic liver disease. Clin Gastroenterol Hepatol 2004, 2(11): 947-56.
64. Mayer, K.É., Myers, R.P., Lee, S.S. Silymarin treatment of viral hepatitis: A systematic review. J Viral Hepat 2005, 12(6): 559-67.
65. Wohlfarth, C., Efferth, T. Natural products as promising drug candidates for the treatment of hepatitis B and C. Acta Pharmacol Sin 2009, 30(1): 25-30.
66. Berdichevsky, Y., Zemel, R., Bachmatov, L. et al. A novel high throughput screening assay for HCV NS3 serine protease inhibitors. J Virol Methods 2003, 107(2): 245-55.
67. Motoo, Y., Mouri, H., Ohtsubo, K., Yamaguchi, Y., Watanabe, H., Sawabu, N. Herbal medicine Ninjinyoeito ameliorates ribavirin-induced anemia in chronic hepatitis C: A randomized controlled trial. World J Gastroenterol 2005, 11(26): 4013-7.
68. Sabbioni, C., Mandrioli, R., Ferranti, A. et al. Separation and analysis of glycyrrhizin, 18 beta-glycyrrhetic acid and 18 alpha-glycyrrhetic acid in liquorice roots by means of capillary zone electrophoresis. J Chromatogr A 2005, 1081(1): 65-71.
69. Arase, Y., Ikeda, K., Murashima, N. et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997, 79: 1494-500.
70. Suzuki, H., Ohta, Y., Takino, T., Fujisawa, K., Hirayama, C. The therapeutic effects of Stronger Neo Minophagen C for chronic hepatitis. Clin Exp Med 1977, 102: 562-8.
71. Suzuki, H., Ohta, Y., Takino, T., Fujisawa, K., Hirayama, C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Double blind trial. Asian Med J 1983, 26: 423-38.
72. Su, X.S., Chen, H.M., Wang, L.Z. et al. Clinical and laboratory observation on the effect of glycyrrhizin in acute and chronic viral hepatitis. J Tradit Chin Med 1984, 4(2): 127-32.
73. Hino, L., Miyakawa, H., Takahashi, J. Effect of large dose of SNMC on the liver histology of chronic active hepatitis. Kan-Tan-Sui 1986, 13: 797-807.
74. Hino, K., Miyaka, H., Kondo, T. Effects of glycyrrhizin therapy on liver histology in chronic aggressive hepatitis. In: Viral Hepatitis C, D and E. T. Shikata, R.H. Purcell, T. Uchida (Eds.). Amsterdam: Excerpta Medica, 1987, 295-303.
75. Wildhirt, E. Experience in Germany with glycyrrhizinic acid for the treatment of chronic viral hepatitis. In: Viral Hepatitis and Liver Disease. K. Nishioka, H. Suzuki, S. Mishiro, T. Oda (Eds.). Tokyo: Spring-Verlag, 1994, 658-61.
76. Ito, A., Hayashi, N., Katayama, K. et al. Effect of glycyrrhizin on viral replication and quasispecies in patients with type C chronic hepatitis. Int Hepatol Commun 1997, 6: 233-8.
77. Van Rossum, T.G.J., Vulto, A.G., Hop, W.C.J., Brouwer, J.T., Niesters, H.G.M., Schalm, S.W. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: A double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 1999, 14(11): 1093-9.
78. Tsubota, A., Kumada, H., Arase, Y. et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: A randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol 1999, 11(10): 1077-83.
79. Rehmann, I., Heinkel, K. Influence of (+)-cyanidanol-3 on acute hepatitis. Results of a double blind study. Med Klin 1977, 72(50): 2159-64.
80. Piazza, M., Guadagnino, V., Picciotto, L., De Mercato, R., Chirianni, A., Orlando, R., Golden, G. Effect of (+)-cyanidanol-3 in acute HAV, HBV, and non-A, non-B viral hepatitis. Hepatology 1983, 3(1): 45-9.
81. Boigk, G., Stroedter, L., Herbst, H., Waldschmidt, J., Riecken, E.O., Schuppan, D. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997, 26(3): 643-9.
82. Flora, K.D., Rosen, H.R., Benner, K.G. The use of naturopathic remedies for chronic liver disease. Am J Gastroenterol 1996, 91(12): 2654-5.
83. Jacobs, B.P., Dennehy, C., Ramirez, G., Sapp, J., Lawrence, V.A. Milk thistle for the treatment of liver disease: A systematic review and meta-analysis. Am J Med 2002, 113(6): 506-15.
84. Dixit, N., Baboota, S., Kohli, K., Ahmad, S., Ali, J. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharm 2007, 39: 172-9.
85. Magliulo, E., Gagliardi, B., Fiori, G.P. Results of a double blind study on the effect of Silymarin in the treatment of acute viral hepatitis, carried out at two medical centers. Med Klin 1978, 73(28-29): 1060-5.
86. Bode, J.C., Schmidt, U., Dürr, H.K. Silymarin for the treatment of acute viral hepatitis? Report of a controlled trial. Med Klin 1977, 72(12): 513-8.
87. Bean P. The use of alternative medicine in the treatment of hepatitis C. Am Clin Lab 2002, 21(4): 19-21.
88. Buzzelli, G., Moscarella, S., Giusti, A., Duchini, A., Marena, C., Lampertico, M. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 1993, 31(9): 456-60.
89. Angulo, P., Patel, T., Jorgensen, R.A., Therneau, T.M., Lindor, K.D. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000, 32(5): 897-900.
90. Ferenci, P., Scherzer, T.-M., Kerschner, H. et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008, 135(5): 1561-7.
91. Chu, M., Mierzwa, R., Truumees, I. et al. Structure of sch 68631: A new hepatitis C virus proteinase inhibitor from Streptomyces sp. Tetrahedron Lett 1996, 37: 7229-32.
92. Chu, M., Mierzwa, R., He, L. et al. Isolation and structure of sch 351633: A novel hepatitis C virus (HCV) NS3 protease inhibitor from the fungus Penicillium griseofulvum. Bioorg Med Chem Lett 1999, 9(14): 1949-52.
93. Hegde, V.R., Pu, H.Y., Patel, M. et al. Two antiviral compounds from the plant Stylogne cauliflora as inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 2003, 13(17): 2925-8.
94. Li, J.Q., Li, C.Q., Zeng, M.D. et al. Preliminary study on therapeutic effect of oxymatrine in treating patients with chronic hepatitis C. Chin J Intergr Tradit Western Med 1998, 18: 227-9.
95. Chen, X.S., Wang, G.J., Cai, X., Yu, H.Y., Hu, Y.P. Inhibition of hepatitis B virus by oxymatrine in vivo. World J Gastroenterol 2001, 7(1): 49-52.
96. Yu, Y.Y., Wang, Q.H., Zhu, L.M. et al. A clinical research on oxymatrine for the treatment of chronic hepatitis B. Chin J Hepatol 2002, 10: 280-2.
97. Xiang, X.X., Wang, G.J., Cai, X., Li, Y.L. Effect of oxymatrine on murine fulminant hepatitis and hepatocyte apoptosis. Chin Med J 2002, 115(4): 593-6.
98. Song, J., Wang, L.L., Zhu, L., Zhong, H.M., Yao, P. Effects of oxymatrine on procollagen III metabolism and its gene expression in experimental fibrotic rats. Chin J Hepatol 2003, 11: 697.
99. Cai, X., Wang, G.J., Qu, Y., Fan, C.H., Zhang, R.Q., Xu, W.S. Clinical efficacy of kurorinone in the treatment of chronic hepatitis B. Acad J Sec Mil Med Univ 1997, 18: 47-49.
100. l00. Wang, B.-E. Treatment of chronic liver diseases with traditional Chinese medicine. Management of chronic hepatitis B. J Gastroenterol Hepatol 2000, 15(Suppl.): E67-70.
101. Dong, Y.H., Xi, H.L., Yu, Y.Y., Wang, Q.H., Jiang, K., Li, L.Z. Anti-hepatitis B virus mechanism of oxymatrine. Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: A study on the anti-hepatitis B virus mechanism of oxymatrine. J Gastroenterol Hepatol 2002, 17(12): 1299-306.
102. Liu, J., Zhu, M., Shi, R., Yang, M. Radix Sophorae flavescentis for chronic hepatitis B: A systematic review of randomized trials. Am J Chin Med 2003, 31(3): 337-54.
103. Sun, D.X. Chinese medicine matrine con cure Trichomonas vaginalis. Chin J Obstet Gynecol 1958, 6: 544.
104. Tang, Z.W. Report of 60 case acute dysentery treated by matrine. Chin J Intern Med 1960, 8: 357-8.
105. Chen, J.L., Yu, S.Z., Wang, H.J., Yang, G.J., Wang, P.H., Shi, Y. Report of 100 case Giardia lamblia infection treated by matrine. Chin J Intern Med 1965, 13: 614.
106. Qian, Y.K., Cheung, H.T., Richardson, A. Chinese herbs (SFA, LLA) act as immunoregulator to immune cells and cytokine (IL-2, IL-3) in vitro. Chin J Microbiol Immunol 1988, 8: 312-4.
107. Yuan, C., Lu, S. Q., Yao, X. Effects of oxymatrine on the antitumor activity and toxicity of cyclophosphamide in mice. Acta Pharm Sin 1987, 22: 245-9.
108. LiU, J.X., Lu, D.Y., Yang, Z.M., Chen, S.X., Qian, F.R. Preliminary studies on the role of anti coxsackie group B virus of Chinese medicine Sophora flavescens. Acta Univ Med Second Shanghai 1991, 11: 140-2.
109. Chen, F.X., Liu, J.X., Lu, D.Y. The effects of Sophora flavescens alkaloids (SFA) on coxsackie virus B3 (CVB3) in vitro and a preliminary study of its mechanism. Chin J Exp Clin Virol 1995, 9: 115-7.
110. Yang, W.Z., Zeng, M.D., Fan, Z.P. et al. Prophylactic and therapeutic effect of oxymatrine on D-galactosamine-induced rat liver fibrosis. Chin J Hepatol 2002, 10: 193-6.
111. Mao, Y.-M., Zeng, M.-D., Lu, L.-G. et al. Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: A randomized, double blind, placebo-controlled, multicenter clinical study. World J Gastroenterol 2004, 10: 3269-73.
112. Lu, L.G., Zeng, M.D., Mao, Y.M. et al. Oxymatrine therapy for chronic hepatitis B: A randomized double-blind and placebo-controlled multi-center trial. World J Gastroenterol 2003, 9: 2480-3.
113. Chen, Y.X., Li, J.Q., Zeng, M.D. et al. The inhibitory effect of oxymatrine on hepatitis C virus in vitro. Chin J Hepatot 2001, 9(SuppL): 12-4.
114. Chen, X. The effect of hepatitis 20 coses treated by alkaline Sophora flavescens oxide. Chin Clin New Med 2004, 4: 315-6.
115. Liu, J., Liu, Y.P., Klaassen, C.D. The effect of Chinese hepatoprotective medicines on experimental liver injury in mice. J Ethnopharmacol 1994, 42(3): 183-91.
116. Aoki, T., Kojima, T., Kameda, N., Yoshijima, S., Ono, A., Kobayashi, Y. Anti-inflammatory effect of a traditional Chinese medicine, ren-shen-yang-rong-tang (Japanese name: ninjin-youei-to), on alveolar macrophages stimulated by RANTES or TNF-alpha. Arerugi 1994, 43(5): 663-7.
117. Takayama, F., Egashira, T., Yamanaka, Y. Protective effect of Ninjin-yoei-to on damage to isolated hepatocytes following transient exposure to tertbutyl hydroperoxide. Jpn J Pharmacol 2001, 85(3): 227-33.
118. Egashira, T., Takayama, F., Komatsu, Y. Changes of materials that scavenge 1,1-diphenyl-2-picrylhydrazyl radicals in plasma by per-oral administration of Kampo medicine, Ninjin-yoei-to in rats. J Pharm Pharmacol 2003, 55(3): 367-71.
119. Cyong, J.C., Ki, S.M., Iijima, K., Kobayashi, T., Furuya, M. Clinical and pharmacological studies on liver diseases treated with Kampo herbal medicine. Am J Chin Med 2000, 28(3-4): 351-60.
120. Nagai, H., Yakuo, I., Aoki, M. et al. The effect of gomisin A on immunologic liver injury in mice. Planta Med 1989, 55(1): 13-7.
121. Yamada, S., Murawaki, Y., Kawasaki, H. Preventive effect of gomisin A, a lignan component of Shizandra fruits, on acetaminophen-induced hepatotoxicityin rats. Biochem Pharmacol 1993, 46(6): 1081-5.
122. Kubo, S., Ohkura, Y., Mizoguchi, Y. et al. Effect of gomisin A (TJN-101) on liver regeneration. Planta Med 1992, 58(6): 489-92.
123. Maeda, S., Takeda, S., Miyamoto, Y., Aburada, M., Harada, M. Effects of gomisin A on liver functions in hepatotoxic chemicals-treated rats. Jpn J Pharmacol 1985, 38(4): 347-53.
124. Takeda, S., Arai, I., Hasegawa, M., Tatsugi, A., Aburada, M., Hosova, E. Effect of gomisin A (TJN-101), a lignan compound isolated from Schisandra fruits, on liver function in rats. Folia Pharmacol Jpn (Nippon Yakurigaku Zasshi) 1988, 91: 237-44.
125. Melhem, A., Stern, M., Shibolet, O. et al. Treatment of chronic hepatitis C virus infection via antioxidants: Results of a phase I clinical trial. J Clin Gastroenterol 2005, 39(8): 737-42.
126. Hussein, G., Miyashiro, H., Nakamura, N., Hattori, M., Kakiuchi, N., Shimotohno, K. Inhibitory effects of Sudanese medicinal plant extracts on hepatitis C virus (HCV) protease. Phytother Res 2000, 14(7): 510-6.
127. Wagner, H., Bladt, S. Pharmaceutical quality of hypericum extracts. J Geriatr Psychiatry Neurol 1994, 7(Suppl. 1): S65-8.
128. Meruelo, D., Lavie, G., Lavie, D. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: Aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci USA 1988, 85(14): 5230-4.
129. Lavie, G., Valentine, F., Levin, B. et al. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl Acad Sci USA 1989, 86(15): 5963-7.
130. Tang, J., Colacino, J.M., Larsen, S.H., Spitzer, W. Virucidal activity of hypericin against enveloped and non-enveloped DNA and RNA viruses. Antiviral Res 1990, 13(6): 313-25.
131. Kraus, G.A., Pratt, D., Tossberg, J., Carpenter, S. Antiretroviral activity of synthetic hypericin and related analogs. Biochem Biophys Res Commun 1990, 172(1): 149-53.
132. Lenard, J., Rabson, A., Vanderoef, R. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: Inhibition of fusion and syncytia formation. Proc Natl Acad Sci USA 1993, 90(1): 158-62.
133. Moraleda, G., Wu, T.T., Jilbert, A.R. et al. Inhibition of duck hepatitis B virus replication by hypericin. Antivir Res 1993, 20(3): 235-47.
134. Qi, L.Q., Xia, X.S. Anti-hepatitis C virus medicine. Food and Drug 2007, 9: 66-70.
135. Jacobson, J.M., Feinman, L., Liebes, L. et al. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2001, 45(2): 517-24.
136. Dai, J.-R, Carté, B.K., Sidebottom, P.J., Yew, A.L.S., Ng, S.-B., Huang, Y., Butler, M.S. Circumdatin G, a new alkaloid from the fungus Aspergillus ochraceus. J Nat Prod 2001, 64(1): 125-6.
137. Takeshita, N., Kakiuchi, N., Kanazawa, T., Komoda, Y., Nishizawa, M., Tani, T., Shimotohno, K. An enzyme-linked immunosorbent assay for detecting proteolytic activity of hepatitis C virus proteinase. Anal Biochem 1997, 247(2): 242-6.
138. Sudo, K., Matsumoto, Y., Matsushima, M., Konno, K., Shimotohno, K., Shigeta, S., Yokota, T. Novel hepatitis C virus protease inhibitors: 2,4,6-Trihydroxy, 3-nitro-benzamide derivatives. Antiviral Chem Chemother 1997, 8: 541-4.
139. Luo, H.P., Chen, L.R., Li, Z.Q., Ding, Z.S., Xu, X.J. Frontal immunoaffinity chromatography with moss spectrometric detection: A method for finding active compounds from traditional Chinese herbs. Anal Chem 2003, 75(16): 3994-8.
140. Buckwold, V.E., Wilson, R.J.H., Nalca, A. et al. Antiviral activity of hop constituents against a series of DNA and RNA viruses. Antiviral Res 2004, 61(1): 57-62.
141. Nord, L.I., Sørensen, S.B., Duus, J.Ø. Characterization of reduced iso-α-acids derived from hops (Humulus lupulus) by NMR. Magn Reson Chem 2003, 41: 660-70.
142. Wang, Q., Ding, Z.-H., Liu, J.-K., Zheng, Y.-T. Xanthohumol, a novel anti-HIV-1 agent purified from hops Humulus lupulus. Antiviral Res 2004, 64(3): 189-94.
143. Miranda, C.L., Stevens, J.F., Helmrich, A. et al. Antiproliferative and cytotoxic effects of prenylated flavonoids from hop (Humulus lupulus) in human cancer cell lines. Food Chem Toxicol 1999, 37(4): 271-85.
144. Miranda, C.L., Stevens, J.F., Ivanov, V., McCall, M., Frei, B., Deinzer, M.L., Buhler, D.R. Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones in vitro. J Agric Food Chem 2000, 48(9): 3876-84.
145. Duan, D.L., Li, Z.Q., Luo, H.P., Zhang, W., Chen, L.R., Xu, X.J. Antiviral compounds from traditional Chinese medicines Galla Chinese as inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 2004, 14(24): 6041-4.
146. Zhou, Z.-H., Li, M.-L., Chen, G.-Z., Chen, Z.-H., Yang, C.-R.. Phenolic constituents of galls of Quercus variabilis and their activities. Acta Botanica Yunnanica 2001, 23(1): 126-34.
147. Lin, T.-C., Hsu, R.-L., Cheng, J.-T. Antihypertensive activity of corilagin and chebulinic acid, tannins from Lumnitzera racemosa. J Nat Prod 1993, 56(4): 629-32.
148. Zuo, G.-Y., Li, Z.-Q., Chen, L.-R., Xu, X.-J. In vitro anti-HCV activities of Saxifraga melanocentra and its related polyphenolic compounds. Antivir Chem Chemother 2005, 16(6): 393-8.
149. Wang, Y., Li, Z.-Q., Chen, L.-R., Xu, X.-J. Antiviral compounds and one new iridoid glycoside from Cornus officinalis. Prog Nat Sci 2006, 16: 142-6.
150. Hwang, D.-R., Wu, Y.-S., Chang, C.-W. et al. Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system. Bioorg Med Chem 2006, 14(1): 83-91.
151. O'Hara, M., Kiefer, D., Farrell, K., Kemper, K. A review of 12 commonly used medicinal herbs. Arch Fam Med 1998, 7(6): 523-36.
152. Zuo, G.-Y., Li, Z.-Q., Chen, L.-R., Xu, X.-J. Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. Antiviral Res 2007, 76(1): 86-92.
153. Zuo, G.-Y., Li, Z.-Q., Chen, L.-R., He, H.-P., Xu, X.-J. Gallic acid esters of bergenin from Saxifraga melanocentra (Saxifragaceae) and their inhibition against HCVNS3 Protease. Acta Botanica Yunnanica 2007, 29(4): 486-8.
154. Hu, J.-R., Patel, R., Li, B. et al. Anti-HCV bioactivity of pseudoguaianolides from Parthenium hispitum. J Nat Prod 2007, 70(4): 604-7.
155. Lee, H.Y., Yum, J.H., Rho, Y.K. et al. Inhibition of HCV replicon cell growth by 2-arylbenzofuran derivatives isolated from Mori Cortex Radicis. Planta Med 2007, 73(14): 1481-5.
156. Asano, N., Yamashita, T., Yasuda, K. et al. Polyhydroxylated alkaloids isolated from mulberry trees (Morus alba L.) and silkworms (Bombyx mori L.) J Agric Food Chem 2001, 49(9): 4208-13.
157. Jacob, J.R., Mansfield, K., You, J.E., Tennant, B.C., Kim, Y.H. Natural iminosugar derivatives of 1-deoxynojirimycin inhibit glycosylation of hepatitis viral envelope proteins. J Microbiol 2007, 45(5): 431-40.
158. Chapel, C., Garcia, C., Bartosch, B. et al. Reduction of the infectivity of hepatitis C virus pseudoporticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. J Gen Virol 2007, 88(Pt. 4): 1133-43.
159. Steinmann, E., Whitfield, T., Kallis, S., Dwek, R.A., Zitzmann, N., Pietschmann, T., Bartenschlager, R. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 2007, 46(2): 330-8.
160. Na, M.K., Meujo, D.A.F., Kevin, D., Anderson, M., Hill, R.T., Schinazi, R.F., Hamann, M.T. Anti-infective pyrroloiminoquinone alkaloids from a deepwater Alaskan sponge of the genus Latrunculia. Planta Med 2008, 74(9): 1037.
161. Oka, H., Yamamoto, S., Kuroki, T. et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995, 76(5): 743-9.